This week the headline appeared to have some tough news for RNA companies, but Alnylam remains undeterred about the potential of its treatments.» Read More
*L'Oreal buys 8 pct stake from Nestle for 6.5 bln euros. *Nestle stake cut to 23 pct, but says in for long haul. *Deal will boost L'Oreal EPS, Nestle to do share buyback.
*L'Oreal does not need to sell Sanofi stake for Nestle deal. *Hopes recede for debt-funded buyback of stake by Sanofi.
*Bloomberg said Nestle looking to cut L'Oreal stake. Bloomberg reported on Friday that Swiss food group Nestle was looking at ways to reduce its L'Oreal stake, which is currently worth more than 23 billion euros.
LONDON, Feb 10- European shares traded flat on Monday, as cosmetics maker L'Oreal gained on expectations it will buy back its shares owned by Nestle and helped to keep the market steady after its recent gains.
PARIS, Feb 6- French drugmaker Sanofi's forecast for a return to profit growth after three years of decline failed to impress investors on Thursday, sending its shares to a one-year low.
MUMBAI/ LONDON, Feb 6- Global pharmaceutical firms are pressuring the United States to act against India to stop more local companies producing up to a dozen new varieties of cheap generic drugs still on-patent, sources with direct knowledge of the matter said.
PARIS, Feb 6- European shares rose in early trade on Thursday, bouncing back from a sharp two-week selloff, with telecom gear maker Alcatel-Lucent surging 7.4 percent after posting reassuring results. The market's rebound could be limited, however, ahead of a European Central Bank meeting later in the day.
Markets are in wait-and-see mode ahead of Friday's jobs report, but there are a few events Thursday that could sway the market's direction.
Feb 4- Ten big rival drug companies have formed a pact to cooperate on a government-backed effort to accelerate the discovery of new drugs, the Wall Street Journal reported.
Some of the names on the move ahead of the open.
*Sanofi alleges Lilly infringed four patents. *Sanofi, Novo shares rise on delayed biosimilar threat. NEW YORK/ PARIS, Jan 31- French drugmaker Sanofi is suing Eli Lilly and Co for alleged patent infringements concerning its top-selling Lantus diabetes treatment, delaying the U.S. firm's plans to produce a copycat version of Lantus.
Jan 30- French drugmaker Sanofi sued Eli Lilly and Co on Thursday, alleging that the U.S. pharmaceutical company infringed patents on its top-selling diabetes treatment, the insulin product Lantus.
BASEL, Jan 29- Novartis is looking at options, such as joint ventures, for three smaller businesses to bring them in line with its world-leading pharmaceutical operations, it said on Wednesday, in a review due to be completed by the end of summer.
Chris Viehbacher, CEO of Sanofi, says 2013 was a big year for biotech IPOs as companies were coming to market to access cash for the first time after many years.
*Drug firms may threaten to cut South Africa investment. JOHANNESBURG, Jan 17- South Africa on Friday slammed global drug firms over a covert campaign against its planned overhaul of intellectual property laws to favour cheaper generic drugs, accusing pharmaceutical companies of a "satanic" plot to commit "genocide".
JOHANNESBURG, Jan 17- Global drug firms may threaten to cut their South African investments as part of a campaign against Pretoria's plans to overhaul its intellectual property laws to favour generic production, documents seen by Reuters show.
*FTSEurofirst 300 ends up 0.2 pct at 1,326.37 points. *ESTOXX 50 closes up 0.2 pct at 3,119.53 points. LONDON, Jan 14- European shares edged higher on Tuesday, buoyed by gains in major pharmaceutical stocks and by a rebound in U.S. equities after U.S.
SAN FRANCISCO, Jan 13- French drugmaker Sanofi will buy a 12 percent stake in Alnylam Pharmaceuticals Inc for $700 million and deepen their partnership to develop drugs for rare genetic diseases.
Jan 13- French drugmaker Sanofi will buy a 12 percent stake in Alnylam Pharmaceuticals Inc for $700 million and deepen their partnership to develop drugs for rare genetic diseases.
*Novartis may swap animal health, vaccines for Merck's OTC. *Novartis, Merck may each trade $5 bln in assets- Bloomberg. LONDON/ FRANKFURT, Jan 9- Novartis AG is discussing swapping its animal health and human vaccines businesses for Merck& Co Inc's over-the-counter products unit in a deal that could boost earnings at both companies.